10-Q · April 30, 2026
DBV Technologies' latest 10-Q report reveals continued operational challenges, with operating expenses surging 78% year-over-year alongside rising net losses. Despite these headwinds, the company maintains a robust cash…
Earnings analysis · 10-Q
DBVT earnings analysis
Filed July 16, 2026 · Our reading of the company's report
The latest report
DBV Technologies reported Q2 2026 results with zero revenue, consistent with prior expectations, while net loss increased to $50.4 million from $41.9 million year-over-year. The operating expenses rose primarily due to…
Read full summary
DBV Technologies reported Q2 2026 results with zero revenue, consistent with prior expectations, while net loss increased to $50.4 million from $41.9 million year-over-year. The operating expenses rose primarily due to escalated sales and marketing expenses ahead of expected BLA submissions with greater operational capacity requirements.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.12
What stood out
-
Total Revenue at $0
The company did not generate any revenue from operating activities for Q2 2026, consistent with Q2 2025.
-
Net Loss Increases
Net loss escalated to $50.4 million in Q2 2026, a 20% increase from $41.9 million in Q2 2025.
-
Research and Development Expenses Down
R&D expenses decreased to $31.2 million in Q2 2026 from $33.7 million in Q2 2025, a 7% reduction.
-
Sales & Marketing Expenses Surge
Sales and marketing expenses soared to $5.5 million, up 1225% from $0.4 million in Q2 2025, reflecting increased commercialization readiness efforts.
-
General & Administrative Costs Rise
G&A expenses rose to $14.6 million, a 72% increase from $8.5 million in Q2 2025, driven by expansion of corporate infrastructure.
-
Cash Balance Declines
The cash balance as of June 30, 2026, was $174.9 million, down from $194.2 million at the end of 2025.
What to watch
-
Increased Net Losses
Net losses rose to $50.4 million this quarter, indicating higher costs without revenue.
-
Reliance on Third-Party Manufacturers
Dependence on Sanofi and FAREVA for manufacturing exposes the company to risks related to capacity and compliance issues.
-
Foreign Currency Fluctuations
Risks from fluctuations between the Euro and U.S. dollar resulted in a significant foreign currency translation adjustment of $(5.3) million.
Management's outlook
Outlook deferred to earnings press release / call.
Earlier filings 2
10-K · April 30, 2026
DBV Technologies reported a challenging year with revenue declines and substantial operating losses. Despite maintaining cash reserves for ongoing operations, the company is facing scrutiny over its financial…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.